CSL (HAM:CSJ) Inventories, Work In Process: €0 Mil (As of Dec. 2025)


HAM:CSJ CSL Ltd HAM:CSJ
73 GF Score
Price €69.73
GF Value €171.17
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Inventories, Work In Process?

CSL HAM:CSJ +2.20% 73 Inventories, Work In Process is €0 Mil as of Dec. 2025. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €171.17 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. CSL's work in process for the quarter that ended in Dec. 2025 was €0 Mil.

CSL Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for CSL's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Inventories, Work In Process Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,037.17 1,513.13 1,955.84 2,253.75 2,092.07

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,955.84 0.00 2,253.75 2,092.07 0.00
HAM:CSJ
73GF Score
CSL Ltd HAM:CSJ
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €0 Mil mean?
CSL (HAM:CSJ) has a Inventories, Work In Process of €0 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on CSL and its competitors.
Is CSL's Inventories, Work In Process too high?
CSL's current Inventories, Work In Process is €0 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Inventories, Work In Process compare to VRTX and REGN?
CSL's Inventories, Work In Process of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on CSL and its competitors. CSL's current Inventories, Work In Process is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €171.17, compared to a current price of €69.73 — trading 59.3% below its estimated fair value. The current Inventories, Work In Process is €0 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For CSL (HAM:CSJ), the current Inventories, Work In Process is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (HAM:CSJ) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of €69.73 is trading 59.3% below its estimated GF Value™ of €171.17. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for HAM:CSJ:

  • Inventories, Work In Process: €0 Mil
  • GF Value™: €171.17 vs. price of €69.73 (59.3% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for HAM:CSJ

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.73
Price
€171.17
GF Value